BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9753343)

  • 21. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD31 mismatching affects marrow transplantation outcome.
    Grumet FC; Hiraki DD; Brown BWM ; Zehnder JL; Zacks ES; Draksharapu A; Parnes J; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(9):503-12. PubMed ID: 11669217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
    Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
    Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia.
    Yagasaki H; Takahashi Y; Kudo K; Ohashi H; Hama A; Yamamoto T; Tanaka M; Yoshida N; Hidaka H; Nishio N; Kojima S
    Int J Hematol; 2007 Jun; 85(5):437-42. PubMed ID: 17562622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A clinical study of 19 cases of unrelated heterogenic bone marrow transplantation].
    Xu L; Huang X; Ren H; Zhang Y; Guo N; Lu D
    Zhonghua Nei Ke Za Zhi; 2002 Apr; 41(4):256-8. PubMed ID: 12133439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors.
    Leung WH; Turner V; Richardson SL; Benaim E; Hale G; Horwitz EM; Woodard P; Bowman LC
    Hum Immunol; 2001 Apr; 62(4):399-407. PubMed ID: 11295473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
    Wagner JL; Seidel K; Boeckh M; Storb R
    Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
    Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
    Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
    J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
    Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
    J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
    Nishida T; Murayama T; Hirai H; Okamoto S; Sao H; Hara M; Kanamori H; Atsuta Y; Matsuo K; Morishima Y; Kodera Y
    Int J Hematol; 2009 Jan; 89(1):98-105. PubMed ID: 19052693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
    Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
    Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JC
    Bone Marrow Transplant; 2005 Mar; 35(5):467-71. PubMed ID: 15665848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.